SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Mankind Pharma lists with 20.37% premium on the BSE

09 May 2023 Evaluate

Mankind Pharma has debuted at Rs 1300.00 on the BSE, up by 220 points or 20.37% from its issue price of Rs 1080.

The scrip is currently trading at Rs 1388.30, up by 308.30 points or 28.55% from its issue price. It has touched a high and low of Rs 1395.00 and Rs 1300.00 respectively. So far 7.19 lakh shares were traded on the counter.

The offering, which was open for subscription between April 25, 2023 and April 27, 2023 was subscribed over 15 times. The issue price was fixed at Rs 1080 per share i.e. at upper end of price band of Rs 1026-1080 apiece.

Mankind Pharma develops, manufactures, and markets pharmaceutical formulations across various acute and chronic therapeutic areas and several consumer healthcare products.

Mankind Pharma Share Price

2123.20 18.50 (0.88%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×